Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

pharmatech cjsc - fluconazole - solution for i/v infusion - 2mg/ml

Ireland - English - HPRA (Health Products Regulatory Authority)

pfizer limited - fluconazole - solution for infusion - 2 mg/ml - triazole derivatives

Israel - English - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - fluconazole - solution for infusion - fluconazole 2 mg/ml - fluconazole - fluconazole - fluconazole is indicated in the following fungal infections .fluconazole is indicated in adults for the treatment of:• cryptococcal meningitis .• coccidioidomycosis . invasive candidiasis.• mucosal candidiasis (including oropharyngeal candidiasis, oesophageal candidiasis, candiduria and chronic mucocutaneous candidiasis).• chronic oral atrophic candidiasis (denture sore mouth) if dental hygiene topical treatment are insufficient.fluconazole is indicated in adults for the prophylaxis of:• relapse of cryptococcal meningitis in patients with high risk of recurrence.• relapse of oropharyngeal or oesophageal candidiasis in patients infected with hiv who are at high risk of experiencing relapse.• prophylaxis of candidal infections in patients with prolonged neutropenia (such as patients with haematological malignancies receiving chemotherapy or patients receiving haematopoetic stem cell transplantation ).fluconazole is indicated in term newborn infants, infants, toddlers, children and adolescents aged from 0 to 17 years old:fluconazole is used for the treatment of mucosal candidiasis (oropharyngeal, oesophageal), invasive candidiasis, cryptococcal meningitis and the prophylaxis of candidal infections in immunocompromised patients. fluconazole can be used as maintenance therapy to prevent relapse of cryptococcal meningitis in children with high risk of reoccurrence.therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly.consideration should be given to official guidance on the appropriate use of antifungals.

Israel - English - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - fluconazole - powder for suspension - fluconazole 50 mg / 5 ml - fluconazole - fluconazole - fluconazole is indicated in the following fungal infections.fluconazole is indicated in adults for the treatment of:• cryptococcal meningitis.• coccidioidomycosis.• invasive candidiasis.• mucosal candidiasis including oropharyngeal, oesophageal candidiasis, candiduria and chronic mucocutaneous candidiasis.• chronic oral atrophic candidiasis (denture sore mouth) if dental hygiene or topical treatment are insufficient.• vaginal candidiasis, acute or recurrent; when local therapy is not appropriate.• candidal balanitis when local therapy is not appropriate.• dermatomycosis including tinea pedis, tinea corporis, tinea cruris, tinea versicolor and dermal candida infections when systemic therapy is indicated.• tinea unguinium (onychomycosis) when other agents are not considered appropriate.fluconazole is indicated in adults for the prophylaxis of:• relapse of cryptococcal meningitis in patients with high risk of recurrence.• relapse of oropharyngeal or oesophageal candidiasis in patients infected with hiv who are at high risk of experiencing relapse.• to reduce the incidence of recurrent vaginal candidiasis (4 or more episodes a year).• prophylaxis of candidal infections in patients with prolonged neutropenia (such as patients with haematological malignancies receiving chemotherapy or patients receiving hematopoietic stem cell transplantation).fluconazole is indicated in term newborn infants, infants, toddlers, children, and adolescents aged from 0 to 17 years old:fluconazole is used for the treatment of mucosal candidiasis (oropharyngeal, oesophageal), invasive candidiasis, cryptococcal meningitis and the prophylaxis of candidal infections in immunocompromised patients. fluconazole can be used as maintenance therapy to prevent relapse of cryptococcal meningitis in children with high risk of reoccurrence. therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti infective therapy should be adjusted accordingly.consideration should be given to official guidance on the appropriate use of antifungals.

Israel - English - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - fluconazole - capsules - fluconazole 200 mg - fluconazole - fluconazole - fluconazole is indicated in the following fungal infections.fluconazole is indicated in adults for the treatment of:• cryptococcal meningitis.• coccidioidomycosis.• invasive candidiasis.• mucosal candidiasis including oropharyngeal, oesophageal candidiasis, candiduria and chronic mucocutaneous candidiasis.• chronic oral atrophic candidiasis (denture sore mouth) if dental hygiene or topical treatment are insufficient.• vaginal candidiasis, acute or recurrent; when local therapy is not appropriate.• candidal balanitis when local therapy is not appropriate.• dermatomycosis including tinea pedis, tinea corporis, tinea cruris, tinea versicolor and dermal candida infections when systemic therapy is indicated.• tinea unguinium (onychomycosis) when other agents are not considered appropriate.fluconazole is indicated in adults for the prophylaxis of:• relapse of cryptococcal meningitis in patients with high risk of recurrence.• relapse of oropharyngeal or oesophageal candidiasis in patients infected with hiv who are at high risk of experiencing relapse.• to reduce the incidence of recurrent vaginal candidiasis (4 or more episodes a year).• prophylaxis of candidal infections in patients with prolonged neutropenia (such as patients with haematological malignancies receiving chemotherapy or patients receiving hematopoietic stem cell transplantation).fluconazole is indicated in term newborn infants, infants, toddlers, children, and adolescents aged from 0 to 17 years old:fluconazole is used for the treatment of mucosal candidiasis (oropharyngeal, oesophageal), invasive candidiasis, cryptococcal meningitis and the prophylaxis of candidal infections in immunocompromised patients. fluconazole can be used as maintenance therapy to prevent relapse of cryptococcal meningitis in children with high risk of reoccurrence. therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti infective therapy should be adjusted accordingly.consideration should be given to official guidance on the appropriate use of antifungals.

Israel - English - Ministry of Health

trima israel pharmaceutical products maabarot ltd - fluconazole - solution for infusion - fluconazole 2 mg/ml - fluconazole - fluconazole - stabilanol is indicated in the following fungal infections .stabilanol is indicated in adults for the treatment of: • cryptococcal meningitis .• coccidioidomycosis. invasive candidiasis.• mucosal candidiasis including oropharyngeal, oesophageal candidiasis, candiduria and chronic mucocutaneous candidiasis.• chronic oral atrophic candidiasis (denture sore mouth) if dental hygiene or topical treatment are insufficient.stabilanol is indicated in adults for the prophylaxis of: • relapse of crytopcoccal meningitis in patients with high risk of recurrence.• relapse of oropharyngeal or oesophageal candidiasis in patients infected with hiv who are at high risk of experiencing relapse.• prophylaxis of candidal infections in patients with prolonged neutropenia (such as patients with haematological malignancies receiving chemotherapy or patients receiving hematopoietic stem cell transplantation ).stabilanol is indicated in term newborn infants, infants, toddlers, children and adolescents aged from 0 to 17 years old: stabilanol is used for the treatment of mucosal candidiasis (oropharyngeal, oesophageal), invasive candidiasis, cryptococcal meningitis and the prophylaxis of candidal infections in immunocompromised patients. stabilanol can be used as maintenance therapy to prevent relapse of cryptococcal meningitis in children with high risk of reoccurrence.therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly.consideration should be given to official guidance on the appropriate use of antifungals.

Israel - English - Ministry of Health

trima israel pharmaceutical products maabarot ltd - fluconazole - solution for infusion - fluconazole 2 mg/ml - fluconazole - fluconazole - stabilanol is indicated in the following fungal infections .stabilanol is indicated in adults for the treatment of: • cryptococcal meningitis .• coccidioidomycosis. invasive candidiasis.• mucosal candidiasis including oropharyngeal, oesophageal candidiasis, candiduria and chronic mucocutaneous candidiasis.• chronic oral atrophic candidiasis (denture sore mouth) if dental hygiene or topical treatment are insufficient.stabilanol is indicated in adults for the prophylaxis of: • relapse of crytopcoccal meningitis in patients with high risk of recurrence.• relapse of oropharyngeal or oesophageal candidiasis in patients infected with hiv who are at high risk of experiencing relapse.• prophylaxis of candidal infections in patients with prolonged neutropenia (such as patients with haematological malignancies receiving chemotherapy or patients receiving hematopoietic stem cell transplantation ).stabilanol is indicated in term newborn infants, infants, toddlers, children and adolescents aged from 0 to 17 years old: sta

Israel - English - Ministry of Health

trima israel pharmaceutical products maabarot ltd - fluconazole - solution for infusion - fluconazole 2 mg/ml - fluconazole - fluconazole - stabilanol is indicated in the following fungal infections .stabilanol is indicated in adults for the treatment of: • cryptococcal meningitis .• coccidioidomycosis. invasive candidiasis.• mucosal candidiasis including oropharyngeal, oesophageal candidiasis, candiduria and chronic mucocutaneous candidiasis.• chronic oral atrophic candidiasis (denture sore mouth) if dental hygiene or topical treatment are insufficient.stabilanol is indicated in adults for the prophylaxis of: • relapse of crytopcoccal meningitis in patients with high risk of recurrence.• relapse of oropharyngeal or oesophageal candidiasis in patients infected with hiv who are at high risk of experiencing relapse.• prophylaxis of candidal infections in patients with prolonged neutropenia (such as patients with haematological malignancies receiving chemotherapy or patients receiving hematopoietic stem cell transplantation ).stabilanol is indicated in term newborn infants, infants, toddlers, children and adolescents aged from 0 to 17 years old: sta

Israel - English - Ministry of Health

trima israel pharmaceutical products maabarot ltd - fluconazole - solution for infusion - fluconazole 2 mg/ml - fluconazole - fluconazole - stabilanol is indicated in the following fungal infections .stabilanol is indicated in adults for the treatment of: • cryptococcal meningitis .• coccidioidomycosis. invasive candidiasis.• mucosal candidiasis including oropharyngeal, oesophageal candidiasis, candiduria and chronic mucocutaneous candidiasis.• chronic oral atrophic candidiasis (denture sore mouth) if dental hygiene or topical treatment are insufficient.stabilanol is indicated in adults for the prophylaxis of: • relapse of crytopcoccal meningitis in patients with high risk of recurrence.• relapse of oropharyngeal or oesophageal candidiasis in patients infected with hiv who are at high risk of experiencing relapse.• prophylaxis of candidal infections in patients with prolonged neutropenia (such as patients with haematological malignancies receiving chemotherapy or patients receiving hematopoietic stem cell transplantation ).stabilanol is indicated in term newborn infants, infants, toddlers, children and adolescents aged from 0 to 17 years old: sta

Ireland - English - HPRA (Health Products Regulatory Authority)

pfizer limited - fluconazole - powder for oral suspension - 40 mg/ml - triazole derivatives